BioWorld-International-2010-09-08
Pooled Phase III Data Underline Microplasmin's Efficacy in VMA
Santhera, Ipsen Sign $181M Collaboration for Fipamezole
Shares in Santhera Pharmaceuticals AG rose more than 8 percent Friday on news of a European partnering deal with Ipsen Group SA, worth up to €141 million (US$181 million), for its Parkinson's drug Fipamezole. (BioWorld International)

